Proteases-From Basic Structure to Function to Drug Design as Targeted Therapy

• Eará dahkkit: Kwok, Hang Fai (Doaimmaheaddji), Shaw, Christopher (Doaimmaheaddji), Walker, Brian (Doaimmaheaddji)
• Materiálatiipa: Elektrovnnalaš Girjji oassi
• Giella: eaŋgalasgiella
• Almmustuhtton: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021
• Fáttát: Research & information: general; MMP; MMP2; MMP9; MMP7; MMP14; matrix metalloproteases; PDAC; pancreatic cancer; Bowman-Birk inhibitor; ranacyclin; trypsin inhibitor; structure-activity relationship; synergistic effect; Gentamicin; matrix metalloproteinase; extracellular matrix; nuclei; cancer; apoptosis; immune response; cysteine protease inhibitor; stefin; signal peptide; parasite; phylogenetic analysis; diversification; protein structure; vascular endothelial growth factors (VEGFs); VEGF-A; PlGF; VEGF-B; VEGF-C; VEGF-D; angiogenesis; lymphangiogenesis; CCBE1; proteases; ADAMTS3; plasmin; cathepsin D; KLK3; prostate-specific antigen (PSA); thrombin; wound healing; metastasis; proteolytic activation; vascular biology; lymphedema
• Liŋkkat: DOAB: download the publication; DOAB: description of the publication

In the two last decades, proteases have constituted one of the primary and important targets in drug discovery. The U.S. FDA has approved more than 12 protease therapies in the last 10 years, and a number of next-generation or completely new proteases are under clinical development. Protease inhibit...